Syndax Pharmaceuticals Stock Analysis

SNDX Stock  USD 9.73  0.27  2.85%   
Syndax Pharmaceuticals is undervalued with Real Value of 15.6 and Target Price of 34.36. The main objective of Syndax Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Syndax Pharmaceuticals is worth, separate from its market price. There are two main types of Syndax Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The Syndax Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Syndax Pharmaceuticals is usually not traded on Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day. Syndax Stock trading window is adjusted to America/New York timezone.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Syndax Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
For more information on how to buy Syndax Stock please use our How to Invest in Syndax Pharmaceuticals guide.

Syndax Stock Analysis Notes

About 99.0% of the company shares are owned by institutional investors. The book value of Syndax Pharmaceuticals was at this time reported as 2.5. The company has Price/Earnings (P/E) ratio of 126.11. Syndax Pharmaceuticals recorded a loss per share of 3.85. The entity had not issued any dividends in recent years. Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts. Syndax Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 59 people. To find out more about Syndax Pharmaceuticals contact Michael MBA at 781 419 1400 or learn more at https://syndax.com.

Syndax Pharmaceuticals Investment Alerts

Syndax Pharmaceuticals generated a negative expected return over the last 90 days
Syndax Pharmaceuticals has high historical volatility and very poor performance
Syndax Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 23.68 M. Net Loss for the year was (318.76 M) with loss before overhead, payroll, taxes, and interest of (199.64 M).
Syndax Pharmaceuticals currently holds about 350.71 M in cash with (274.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.82.
Syndax Pharmaceuticals has a poor financial position based on the latest SEC disclosures
Over 99.0% of the company shares are owned by institutional investors
Latest headline from news.google.com: UBS Group Cuts Syndax Pharmaceuticals Price Target to 35.00 - MarketBeat

Syndax Pharmaceuticals Upcoming and Recent Events

Earnings reports are used by Syndax Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
27th of February 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Syndax Largest EPS Surprises

Earnings surprises can significantly impact Syndax Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-03-08
2020-12-31-0.49-0.440.0510 
2019-11-07
2019-09-30-0.47-0.410.0612 
2016-08-09
2016-06-30-0.53-0.470.0611 
View All Earnings Estimates

Syndax Pharmaceuticals Environmental, Social, and Governance (ESG) Scores

Syndax Pharmaceuticals' ESG score is a quantitative measure that evaluates Syndax Pharmaceuticals' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Syndax Pharmaceuticals' operations that may have significant financial implications and affect Syndax Pharmaceuticals' stock price as well as guide investors towards more socially responsible investments.

Syndax Stock Institutional Investors

Shares
Franklin Resources Inc2025-03-31
2.1 M
Assenagon Asset Management Sa2025-06-30
M
Geode Capital Management, Llc2025-03-31
M
Kingdon Capital Management Llc2025-03-31
M
Woodline Partners Lp2025-03-31
1.9 M
Balyasny Asset Management Llc2025-03-31
1.8 M
Catalio Capital Management, Lp2025-03-31
1.7 M
Ubs Group Ag2025-03-31
1.7 M
Sphera Funds Management Ltd.2025-03-31
1.7 M
Blackrock Inc2025-03-31
8.5 M
Kynam Capital Management, Lp2025-03-31
8.5 M
Note, although Syndax Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Syndax Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 814.01 M.

Syndax Profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(0.44)(0.46)
Return On Capital Employed(0.55)(0.57)
Return On Assets(0.44)(0.46)
Return On Equity(1.11)(1.05)

Management Efficiency

Syndax Pharmaceuticals has return on total asset (ROA) of (0.3629) % which means that it has lost $0.3629 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.937) %, meaning that it created substantial loss on money invested by shareholders. Syndax Pharmaceuticals' management efficiency ratios could be used to measure how well Syndax Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.46 in 2025. Return On Capital Employed is likely to drop to -0.57 in 2025. At this time, Syndax Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 127.8 M in 2025, whereas Non Currrent Assets Other are likely to drop slightly above 206.2 K in 2025.
Last ReportedProjected for Next Year
Book Value Per Share 3.37  3.38 
Tangible Book Value Per Share 3.37  3.38 
Enterprise Value Over EBITDA(4.22)(4.43)
Price Book Value Ratio 3.93  4.13 
Enterprise Value Multiple(4.22)(4.43)
Price Fair Value 3.93  4.13 
Enterprise Value1.3 B1.4 B
Management at Syndax Pharmaceuticals focuses on leveraging technology and optimizing operations. We evaluate the impact of these focuses on the company's financial health and stock performance.
Operating Margin
(4.17)
Beta
0.745
Return On Assets
(0.36)
Return On Equity
(0.94)

Technical Drivers

As of the 22nd of July, Syndax Pharmaceuticals has the Variance of 24.3, risk adjusted performance of (0.01), and Coefficient Of Variation of (4,658). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Syndax Pharmaceuticals, as well as the relationship between them.

Syndax Pharmaceuticals Price Movement Analysis

The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. The Simple Moving Average indicator is calculated by adding the closing price of Syndax Pharmaceuticals for a given number of time periods and then dividing this total by the number of time periods. It is used to smooth out Syndax Pharmaceuticals short-term fluctuations and highlight longer-term trends or cycles.

Syndax Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Syndax Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Syndax Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Syndax Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Metzger Michael A few days ago
Disposition of 7534 shares by Metzger Michael A of Syndax Pharmaceuticals at 9.285 subject to Rule 16b-3
 
Botwood Nicholas A.j. over two months ago
Acquisition by Botwood Nicholas A.j. of 11765 shares of Syndax Pharmaceuticals at 8.995 subject to Rule 16b-3
 
Goldan Keith A. over three months ago
Acquisition by Goldan Keith A. of 23400 shares of Syndax Pharmaceuticals subject to Rule 16b-3
 
Metzger Michael A over three months ago
Acquisition by Metzger Michael A of 6074 shares of Syndax Pharmaceuticals at 7.2 subject to Rule 16b-3
 
Ordentlich Peter over three months ago
Disposition of 17428 shares by Ordentlich Peter of Syndax Pharmaceuticals at 25.8437 subject to Rule 16b-3
 
Gallagher Neil over six months ago
Acquisition by Gallagher Neil of 69375 shares of Syndax Pharmaceuticals at 22.28 subject to Rule 16b-3
 
Jarrett Jennifer over a year ago
Acquisition by Jarrett Jennifer of 17000 shares of Syndax Pharmaceuticals subject to Rule 16b-3
 
Peter Ordentlich over a year ago
Acquisition by Peter Ordentlich of 90000 shares of Syndax Pharmaceuticals at 28.55 subject to Rule 16b-3
 
Briggs Morrison over a year ago
Acquisition by Briggs Morrison of 52855 shares of Syndax Pharmaceuticals at 8.77 subject to Rule 16b-3
 
Dennis Podlesak over a year ago
Acquisition by Dennis Podlesak of 34000 shares of Syndax Pharmaceuticals subject to Rule 16b-3
 
Peter Ordentlich over a year ago
Exercise or conversion by Peter Ordentlich of 7572 shares of Syndax Pharmaceuticals subject to Rule 16b-3

Syndax Pharmaceuticals Outstanding Bonds

Syndax Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Syndax Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Syndax bonds can be classified according to their maturity, which is the date when Syndax Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Syndax Pharmaceuticals Predictive Daily Indicators

Syndax Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Syndax Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Syndax Pharmaceuticals Corporate Filings

F4
18th of July 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
8K
26th of June 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F4
19th of May 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
8K
16th of May 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
9th of May 2025
Other Reports
ViewVerify
7th of May 2025
Other Reports
ViewVerify
8K
5th of May 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
17th of April 2025
Other Reports
ViewVerify

Syndax Pharmaceuticals Forecast Models

Syndax Pharmaceuticals' time-series forecasting models are one of many Syndax Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Syndax Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Syndax Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Syndax Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Syndax shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Syndax Pharmaceuticals. By using and applying Syndax Stock analysis, traders can create a robust methodology for identifying Syndax entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(12.11)(12.72)
Operating Profit Margin(12.91)(13.56)
Net Loss(12.11)(12.72)
Gross Profit Margin 1.11  1.08 

Current Syndax Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Syndax analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Syndax analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
34.36Strong Buy12Odds
Syndax Pharmaceuticals current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Syndax analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Syndax stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Syndax Pharmaceuticals, talking to its executives and customers, or listening to Syndax conference calls.
Syndax Analyst Advice Details

Syndax Stock Analysis Indicators

Syndax Pharmaceuticals stock analysis indicators help investors evaluate how Syndax Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Syndax Pharmaceuticals shares will generate the highest return on investment. By understating and applying Syndax Pharmaceuticals stock analysis, traders can identify Syndax Pharmaceuticals position entry and exit signals to maximize returns.
Begin Period Cash Flow295.6 M
Long Term Debt331.6 M
Common Stock Shares Outstanding85.6 M
Total Stockholder Equity288.1 M
Total Cashflows From Investing Activities-219.8 M
Property Plant And Equipment NetM
Cash And Short Term Investments572.9 M
Cash154.1 M
Accounts Payable11.6 M
Net Debt191.7 M
50 Day M A9.933
Total Current Liabilities103.5 M
Other Operating Expenses363.4 M
Non Current Assets Total121.8 M
Non Currrent Assets Other217 K
Stock Based Compensation43 M

Additional Tools for Syndax Stock Analysis

When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.